Predicting major clearance pathways of drugs is important in understanding their pharmacokinetic properties in clinical use, such as drug-drug interactions and genetic polymorphisms, and their subsequent pharmacological/toxicological effects. In this study, we established an in silico classification method to predict the major clearance pathways of drugs by identifying the boundaries of physicochemical parameters in empirical decisions for each clearance pathway. It requires only four physicochemical parameters [charge, molecular weight (MW), lipophilicity (log D), and protein unbound fraction in plasma (f up )] that were predicted from their molecular structures without performing any benchwork experiments. The training dataset consisted of 141 approved drugs whose major clearance pathways were determined to be metabolism by CYP3A4, CYP2C9, and CYP2D6, hepatic uptake by OATPs, or renal excretion in an unchanged form. After grouping by charge, each drug was plotted in a three-dimensional space according to three axes of MW, log D, and f up . Then, rectangular boxes for each clearance pathway were drawn mathematically under the criterion of "maximizing F value (harmonic mean of precision and recall) with minimum volume," yielding to a precision of 88%, which was confirmed through two types of validation: leave-one-out method and validation using a new dataset. With further modification toward multiple pathways and/or other pathways, not only would this in silico classification system be useful for industrial scientists at the early stage of drug development, which can lead to the selection of candidate compounds with optimal pharmacokinetic properties, but also for regulators in evaluating new drugs and giving regulatory requirements that are pharmacokinetically reasonable.
Once a drug enters the human body, it undergoes detoxification by the complementary functions of a wide variety of metabolic enzymes and transporters, resulting in numerous clearance pathways such as urinary elimination through glomerular filtration and renal tubular excretion, passive diffusion into the liver followed by hepatic metabolism by cytochrome P450 (P450) enzymes to an inactive metabolite, or hepatic uptake by transporters followed by excretion into the bile and then into the feces. The major clearance pathway of drugs is one of the most important pharmacokinetic features relevant for its clinical use. Understanding the major clearance pathways would enable prediction of the changes in the systemic exposure of a drug caused by drug-drug interactions or genetic polymorphisms of enzymes and transporters. Some drugs have been withdrawn from the market owing to fatal side effects that often occurred by drug-drug interactions of their major clearance pathways, such as cerivastatin and its interaction with gemfibrozil (Shitara et al., 2004) . The withdrawals might have been avoided by clarifying their major clearance pathways in the human body and by recognizing the severity of drug interactions, leading to better decision-making before approval or on postmarketing regulatory actions. Risk management of drugs can be promoted by individualized dose adjustments in accordance with its major clearance pathways, such as the dose adjustment recommended for the antitumor agent irinotecan, which is based on the patients' genotype for UDP glucuronosyltransferase (UGT) 1A1 to avoid severe neutropenia caused by excess exposure of SN-38, the active metabolite of irinotecan. Genetic polymorphisms of the organic anion-transporting polypeptide (OATP) 1B1, which mediates the major clearance pathway of the anti-hyperlipidemic agent simvastatin acid, are reported to be associated with the occurrence of myopathy (SEARCH Collaborative Group et al., 2008) . Thus, clarification of the major clearance pathways could enhance risk management of marketed drugs by individualizing the dose or by taking regulatory action. Drug regula-tors are responsible to their citizenry for securing the efficacy and safety of drugs. Pharmacokinetic features of concern include specific genotypes of drug-metabolizing enzymes and transporters, the frequency of mutation in a particular geographic region, and interactions with other drugs used in that region. For example, there is a broad regional diversity in the types and frequencies of genetic mutations of CYP2D6 (Ingelman-Sundberg, 2005) . In whites, there are null mutations (CYP2D6*4) in which allele frequency is 1%, but this type of mutation is not found in Asians. Alternatively, Asians have a mutation with decreased activity (CYP2D6*10) in which the allele frequency is 51%, which is not seen in whites. Therefore, one can see that regulators in Japan or other Asian countries would have a different point of view concerning the pharmacokinetics of drugs metabolized by CYP2D6. Nevertheless, new drug consultation and evaluation between the industry and regulatory authority occurs even before clinical development, with limited observational data. In these situations, in silico prediction systems could assist decisions on the requirements of certain studies; for example, in vitro studies that are not documented in guidelines, drug-interaction studies both in vitro and in vivo, genotyping of subjects in clinical trials, or clinical trials in special populations such as renal-or hepatic-impaired patients.
In vitro experiments can elucidate intrinsic clearance catalyzed by each metabolic enzyme and transporter, but their functions cannot be quantitatively investigated using in vitro methods alone. In silico prediction of pharmacokinetic parameters has been used mainly by researchers involving the initial stage of drug discovery. There are currently few in silico prediction systems commercially available to predict in vivo major clearance pathways of compounds. By using some in vitro systems in addition to an in silico prediction, compounds with inappropriate pharmacokinetic properties can be screened out before preclinical studies. There are some simple empirical classification systems that are generally applied in drug evaluation. For example, the Biopharmaceutics Drug Disposition Classification System (BDDCS) (Wu and Benet, 2005) divides compounds into four classes according to their solubility and extent of metabolism to predict their disposition, interaction, and transporter-enzyme interplay. However, the BDDCS does not tell us which P450 isozyme or transporter determines the overall clearance of drugs. Therefore, we here established an in silico method to predict the major clearance pathways with only four physicochemical parameters easily obtained or predicted from chemical structures.
Materials and Methods
Original Dataset. A dataset was made using the Appendix of Goodman and Gilman's The Pharmacological Basis of Therapeutics (Benet et al., 1996; Thummel et al., 2001 Thummel et al., , 2006 ) with the addition of major OATP substrates. Information concerning clearance pathways in humans was collected from published data; for example, Japanese package inserts, Japanese interview forms, U.S. Food and Drug Administration labels, and research articles. Pharmacokinetic profiles after intravenous administration and in vitro data on metabolism were also collected. If human pharmacokinetic studies consisted of only oral administration data, they were reconsidered with bioavailability.
Training Dataset. Drugs that met the criteria for the following five clearance pathways were selected for the training dataset: metabolism by CYP2C9, CYP2D6, or CYP3A4, renal excretion, or hepatic uptake by OATP transport-FIG. 1. Scheme of the rectangular method. Drugs were plotted in a three-dimensional space according to their MW, log D, and f up , and rectangular boundaries for each group were determined mathematically under the rectangular method. 
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at ASPET Journals on June 27, 2017 dmd.aspetjournals.org ers. Clearance pathways, including nonhepatic pathways and non-P450 pathways, were evaluated by at least two experienced researchers per drug. In many cases, published data did not directly indicate the clearance pathways; therefore, we had to interpret and integrate several data together to evaluate the type and contribution of the pathways for each drug. For example, we often saw information such as "this drug is mainly metabolized by CYP2D6" with experimental data with expressed human microsomes, which does not always mean that its major clearance pathway is CYP2D6. The amount of renal excretion of the parent drug, and not the radioactivity in urine after administration of the 14 C-labeled drug, and also the possibility of direct conjugation were investigated and integrated to determine which pathway contributes most. Drugs were categorized into "renal" if more than 50% of the intravenously administered dose is excreted unchanged into the urine, although for some drugs, it was difficult to distinguish the urinary excreted metabolites from the parent drug. Drugs whose major clearance pathway was attributed to CYP3A4, CYP2C9, or CYP2D6 were allocated in each group. Drugs that are not only substrates of OATP1B1 or OATP1B3 but also whose hepatic influx process is thought to be the rate-limiting step in its hepatic clearance were included in the OATP group. For example, anionic drugs such as HMG-CoA reductase inhibitors and angiotensin II receptor inhibitors were included in this group.
Physicochemical Parameters. For the drugs that were selected for the training dataset, their two-dimensional structures were obtained from PubChem Compound Database (http://pubchem.ncbi.nlm.nih.gov/), and their charge, defined as the charge of the largest fraction at pH ϭ 7.0, was obtained using ADMET Predictor (Simulations Plus, Lancaster, CA). The drugs were then categorized by charge at neutral pH into the following three groups: "cation or neutral (cation/neutral)," anion, or zwitterion. Then, their lipophilicity (log D) at pH ϭ 7.0 was predicted using SciFinder Scholar 2007 (Chemical Abstracts Service, Columbus, OH). In addition, the protein unbound fraction in plasma (f up ) was predicted using ADME Boxes version 4.0 (Pharma Algorithms, Toronto, ON, Canada) and compared with the performance with the in vivo observed values (if shown as range, median was used), with a view to streamline in silico prediction by incorporating predicted parameters rather than experimental ones. These parameters were chosen based on personal communications with experienced researchers not only in academia but also in the pharmaceutical industry.
Rectangular Method. After dividing these drugs by charge, the drugs were plotted separately in a three-dimensional space consisting of the molecular weight (MW), log D, and the f up axes. The boundaries of each of the five clearance pathways were determined by the criterion of "maximum F value (harmonic mean of precision and recall) with minimum volume" (Fig. 1) . Precision is the number of true positives (i.e., drugs correctly classified to a pathway) divided by the sum of true positives and false positives (i.e., drugs correctly or incorrectly classified to a pathway), and recall is the number of true positives (i.e., drugs correctly classified to a pathway) divided by the sum of true positives and false negatives (i.e., total number of drugs that actually belong to the pathway): dmd.aspetjournals.org
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F value is calculated as below:
where TP, TN, FP, and FN are the number of drugs that were true positive, true negative, false positive, and false negative, respectively. Only when a rectangular boundary was equal to the maximal (or minimal) value in the training dataset, we shifted the rectangular boundary toward a preset upper (or lower) limit of the corresponding parameter to broaden the versatility to any drug-like compound. We determined the preset limits (MW, 70 -2000; log D, Ϫ15 to 10; f up , 0 -1) based on empirical decisions. For example, if the lower boundary of f up for the anionic OATP rectangle were calculated to be 0.003, and if this were the lowest among all the pathways, the boundary would be extended to the preset limit of 0. This whole algorithm was named as the "rectangular method."
Validation. We performed two types of validation to confirm this accuracy: cross-validation by the leave-one-out (LOO) method and validation using a new dataset. LOO is frequently used for cross-validation, and in a dataset with n data, the training is done a total of n times with n Ϫ 1 training data and 1 test data. Another validation was performed with a new test dataset consisting of 36 drugs. These drugs were selected from drugs approved after 2004 and filtered using the same criteria.
Results
The original dataset consisted of 294 drugs, where 230 drugs were allocated into a single major clearance pathway, and 39 drugs were found to have multiple pathways. Of the drugs classified to a single major clearance pathway, 150 drugs met the criteria for the training dataset. Because there were only 9 drugs in the zwitterion group, the remaining 141 drugs were used as the training dataset (Fig. 2) .
The performance of this type of classification system is evaluated by its precision and recall. The presumed users of this classification system would classify compounds whose actual clearance pathways were uninvestigated. From the users' standpoint, the interpretation of precision, which is calculated here as the proportion of drugs correctly classified to the total number of drugs classified to that pathway, would be more practical and informative than recall, which is calculated here as the proportion of drugs correctly classified to the total number of drugs that actually undergo that pathway. 
Actual and classified clearance pathways
Recall refers to the proportion of drugs correctly classified to a pathway to the total number of drugs that actually undergo that pathway. Recall (relaxed) and Accuracy (relaxed) are used when drugs that were classified in a partially correct manner were also regarded as correct (see text and Table 2 ). For example, the recall and the recall (relaxed) for CYP3A4 is 46/52 ϭ 88% and (46 ϩ 1)/52 ϭ 90%, respectively. Precision is the proportion of drugs correctly classified to a pathway to the total number of drugs classified to that pathway. a Drugs that were classified correctly. b Although the major clearance pathways of these four drugs ͓glimepiride, glipizide, glyburide (glibenclamide), and irbesartan͔ were to be CYP2C9 (Naritomi et al., 2004; Kirchheiner et al., 2005) , we have experimentally confirmed that they are substrates of OATP (K. Yoshida and Y. Debori, unpublished data).
TABLE 2

Comparison between the actual and classified pathways: drugs classified as dual pathways
Charge and Drug Name Classified Pathway 
Glipizide - 
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The f up values observed in vivo correlated well with those predicted by ADME Boxes (r ϭ 0.91; Pharma Algorithms) (Fig. 3) . The rectangular boundaries were determined using both the observed and predicted f up , and the classification performance (precision and recall) was found to be similar (data not shown). Thus, we decided to eliminate all the observational data for this investigation, and the rectangular boundaries were drawn using only parameters predicted from the two-dimensional molecular structures (Fig. 4) . In the three-dimensional space, there were spaces where two clearance pathway rectangles overlapped or spaces where there were no rectangular boxes. A drug would be classified to "single pathway," "dual pathway," or "none" (Fig. 5) . In this investigation, the overall precision of the 117 drugs that were classified into single pathway was 88% (Table 1) .
In all 14 drugs that were classified into dual pathway, one of the pathways was the actual major clearance pathway. Therefore, we interpreted these drugs to be partially correct. In 8 of these 14 drugs that were classified into dual pathway, the other pathway was not supported by any observed data. However, in the remaining six drugs, the other pathway was supported by other information: the actual minor clearance pathway in five drugs and an experimentally confirmed pathway in one drug (Table 2) .
When we focused on another 14 drugs that were classified incorrectly into single pathway, 6 drugs were classified into their actual minor pathway, and 4 drugs were classified into the experimentally confirmed pathway (Table 3) . Thus, the majority of these drugs were not completely incorrectly classified. The parameters of the drugs not classified into any pathway were beyond the boundaries of all the rectangular boxes and showed no specific tendency (Table 4) . On the whole, of the 141 drugs in the training dataset, 103 drugs were given a single correct answer (73% accuracy). Furthermore, including the drugs classified in a partially correct manner, 117 drugs were classified into a somewhat correct pathway [83% accuracy (relaxed)]. Validation by LOO resulted in precision and recall of 70 and 51%, respectively, and validation using a new test dataset resulted in precision and recall of 89 and 69%, respectively (Tables 5 and 6 ). The classification results of all the drugs in the training dataset are shown in Table 7 . 1, the parameter of the drug is above the boundary of its actual pathway; 2, the parameter of the drug is below the boundary of its actual pathway.
TABLE 5
Results of validation: LOO method
Recall refers to the proportion of drugs correctly classified to a pathway to the total number of drugs that actually undergo that pathway. Recall (relaxed) and Accuracy (relaxed) are used when drugs that were classified in a partially correct manner were also regarded as correct (see text and Table 2 ). Precision is the proportion of drugs correctly classified to a pathway to the total number of drugs classified to that pathway. 
Classified
Results of validation: new dataset of drugs
Discussion
In this study, we have shown an in silico method to classify drugs into their major clearance pathways without requiring any experimental data. We performed this investigation focusing on the drugs belonging to these five clearance pathways as the training dataset and assessed the validity within drugs of these five pathways. We focused on clearance pathways that are important in clinical use, that is, metabolism by CYP3A4, CYP2C9, and CYP2D6, hepatic uptake by OATP, and renal excretion in an unchanged form. These five clearance pathways are assumed to account for more than 60% of marketed drugs (Williams et al., 2004) and actually accounted for 51% of our original dataset under our criteria. Nevertheless, owing to insufficient human observational data, there is a possibility that some drugs were underevaluated and did not meet our criteria of the major clearance pathway for the training dataset or the new dataset for validation. CYP2C9, CYP2D6, and OATP are the pathways that are subject to interindividual variations because of relatively frequent genetic polymorphisms of enzymes/transporters. CYP3A4 and OATP are the pathways that are sensitive to drug-drug interactions, whereas renal excretion is sensitive to pathophysiological changes in patients.
Drugs that were omitted from our current investigation could be categorized into the rectangular areas when applied to this classification. Instead of forming a sixth category, the drugs that did not fit into these five clearance pathways were excluded from the training dataset because drugs not belonging to these five categories would consist of drugs having a variety of clearance pathways and would not have any uniform tendency of the physicochemical parameters, which is not favorable as a training dataset. In addition, we decided not to integrate the other clearance pathways into the training dataset because we thought that the numbers of drugs in each category would be insufficient for this rectangular method, and because drugs belonging to these five categories accounted for the majority of drugs. Furthermore, our current scope was to establish a classification method with high accuracy for the training dataset that accounts for the majority of drugs, and establishing a classification that would fit all drug-like compounds is a secondary scope, which we will investigate further.
The accuracy was validated by two methods. In general, the performance of LOO degrades compared with using a full dataset for learning. However, in this study, owing to the small number of data points and the nature of the rectangular method (by the volumeminimizing rule, each boundary is set exactly on a critical data point, not between points), we observed clear shrinkage of rectangles in some cases during LOO. Therefore, another validation was performed with a new test dataset consisting of 36 drugs. Considering the nature of LOO, we considered that these validations support the accuracy of this classification system.
The rectangular boundaries classifying each pathway are in accordance with general empirical rules; for example, drugs that are eliminated unchanged by the kidneys have a small MW, large f up , and small log D (hydrophilic). Although our scope was not to investigate substrate structure-activity relationship for the P450 enzymes and transporters involved in the pathways investigated, our results were generally comparable with previous reports. It has been reported that CYP3A4 allows broader range of substrates in contrast to CYP2C9 and CYP2D6 (Smith, 1991) , which is also observed in our results. Considering molecular size, it has been reported that CYP3A4 substrates are rather large compared with CYP2C9 and CYP2D6 substrates, which are medium-sized (Lewis, 2000) . In our investigation, the dual pathway consisted of only two pairs of pathways, CYP3A4 and CYP2D6, or CYP2C9 and OATP, which are widely known to overlap frequently. Furthermore, the relationship between CYP3A4 and CYP2D6 rectangles in this classification was in accordance with empirical principles that CYP3A4 substrates are commonly more lipophilic (Smith and Jones, 1992) . Regarding charge, our results meet the results of other analyses reporting that CYP2C9 substrates are mostly anionizable compounds and CYP2D6 substrates are cationic compounds (Lewis and Dickins, 2002; Yamashita et al., 2008) . In comparison, substrate structure-activity relationship for OATP substrates has not been much investigated. MW threshold for biliary excretion of parent drugs is reported to be approximately 325 to 400 for rats and 475 for humans (Hirom et al., 1972; Yang et al., 2009) . The lower rectangular boundary of MW for OATP pathway was 360, which was similar to these reported values. Focusing on the distribution of renal drugs and OATP drugs (Fig. 5) , these two groups seem to split around MW ϭ 400. MW may be a determining factor of these two pathways.
To reflect the real world, we must also account for the drugs that undergo multiple clearance pathways. In this investigation, 10% of the drugs were classified into the dual pathway, and in 43% of these drugs, both of the dual pathways were supported by observed or confirmed data. This result indicates that overlapping rectangles may be a clue for multiple pathway prediction. Together with expansion of the numbers of pathways, the overlapping rectangles may be used to identify the multiple pathways, with some quantitative data. We did not expand the numbers of parameters because we believed that the four parameters performed satisfactorily and because complication of this simple classification system would be contrary to our intention. Because one of our future aims is to classify more pathways with the information provided by overlapping rectangles, we might have to put less weight on visual intuitiveness and incorporate other methods such as support vector machine (SVM), decision tree, or neural network. SVM has a broad capacity for classification owing to its ability to find a nonlinear boundary in multidimensional data, although it is difficult to translate the results visually. By using SVM, we can develop a classification system using more parameters.
This in silico classification method never substitutes for in vitro experiments, but this novel prediction method can benefit drug developers in predicting pharmacokinetic properties of drug candidates, especially the contribution ratio of each clearance pathway to the overall clearance of drugs, which is fairly laborious if investigated with in vitro experiments. Moreover, drug developers can add information on major clearance pathways to construct "value-added compound libraries." If they want to avoid developing drug candidates that are sensitive to genetic polymorphisms, they can refrain from selecting compounds that are classified into the CYP2C9 or CYP2D6 pathways at the beginning of drug discovery, without the need for experimental data. Together with physiologically based pharmacokinetic modeling like the one with anti-hyperlipidemic agents (Shitara and Sugiyama, 2006) , organ-specific distribution of compounds could be predicted within the library. Chemists and pharmacokinetic scientists can use this classification system in selecting backbone structures for hit compounds that meet the target molecular structure. Our classification system can help selection of candidate compounds by prioritizing the candidate backbone structures according to their ability to distribute to the target site. Furthermore, the rectangular boundaries observed using our method can offer clues to chemists on how to optimize leading compounds that would have a specific clearance pathway.
These types of classification systems can also be used by drug regulators in drug evaluation as well. Not only the BDDCS mentioned earlier but also Lipinski's Rule of Five (Lipinski, 2003) and the Biopharmaceutics Classification System (BCS) (Yu et al., 2002) are empirical classification systems based on experience and theory that predict categorical data for bioavailability, which is a pharmaceutical property desired for
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at ASPET Journals on June 27, 2017 dmd.aspetjournals.org successful drug development. BCS is used by U.S. Food and Drug Administration drug regulators for biowaivers, and their use is currently under consideration by the European Medicines Agency. That is, BCS Class 1 drugs, which have high solubility and high permeability, will be exempted from bioavailability trials that are required whenever the formulation or manufacturing process changes during clinical development and submission for generic drugs. It is estimated that 30% of drugs are Class 1 drugs (Takagi et al., 2006) . Drug reviewers have long made hard decisions based on observational data, and the application of BCS might be only the beginning for incorporating in silico predictions into regulators' assessments.
In conclusion, our in silico classification system well predicted the clearance pathways of drugs belonging to the five clearance pathways. The rectangular boundaries classifying each pathway were generally in accordance with empirical rules. With further investigation to increase versatility, the pharmacokinetic properties related to drugdrug interaction and the interindividual/interethnic variability as a result of genetic polymorphism and/or renal/hepatic dysfunctions can be optimized, leading to the development and regulatory evaluation toward more effective and less toxic drugs. This web site (http:// www.bi.cs.titech.ac.jp/CPathPred/) has access to the online classification system reported in this study and can be used to classify the major clearance pathways of compounds with the input of their four parameters (charge, MW, log D, and f up ).
